7月马萨诸塞州将停止为公务员和退休人员提供GLP-1减肥药品, Massachusetts will stop covering GLP-1 weight-loss drugs for public workers and retirees in July to save $100–120 million, keeping coverage for diabetes.

马萨诸塞集团保险委员会以预算压力和需要节省1亿至1.2亿美元为由,于7月投票决定停止将GLP-1级药品用于公务员和退休人员体重减肥。 The Massachusetts Group Insurance Commission voted 10-7 to stop covering GLP-1 drugs for weight loss for public employees and retirees, effective July, citing budget pressures and a need to save $100–120 million. 约有22 000名成员因使用肥胖药物而受到影响,尽管糖尿病治疗的覆盖率仍然存在。 The move affects about 22,000 members using the drugs for obesity, though coverage remains for diabetes treatment. 该决定与商业保险商一致,旨在降低保险费,官员希望,这将迫使药品制造商降低价格。 The decision aligns with commercial insurers and aims to reduce premiums, with officials hoping it will pressure drugmakers to lower prices. 批评者警告说,这可能会加剧健康不平等,为削减其他福利开创先例,而全球投资中心预计有3亿美元的国家注入资金来支付索赔。 Critics warn it may worsen health inequities and set a precedent for cutting other benefits, while the GIC expects a $300 million state infusion to cover claims.